Zydus Cadila has received final approval from the US Food & Drug Administration (FDA) to market sevelamer carbonate tablets in the strength of 800 mg.
The drug is a phosphate binder and is used to control phosphorus levels in people with chronic kidney disease who are on dialysis. It helps prevent hypocalcemia (low levels of calcium in the body) caused by elevated phosphorus.
The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.
The group now has 296 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.